Efinopegdutide vs Survodutide
How they differ
- FDA status. Efinopegdutide: No FDA approval reported; studied in clinical trials.1,2 Survodutide: In clinical trials; not FDA-approved.3,4,5
- Kinds of studies cited. Efinopegdutide: smaller controlled human trials. Survodutide: large randomized human trials. How these labels are assigned
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Efinopegdutide | Survodutide |
|---|---|---|
| What it is | An oxyntomodulin analogue conjugated by a polyethylene glycol linker to a human IgG4 Fc fragment, also coded HM12525A and JNJ-64565111, according to FDA’s substance registry.1 | An investigational glucagon receptor and GLP-1 receptor dual agonist from Boehringer Ingelheim, also known as BI 456906.3,6 |
| FDA status | Not FDA-approved No FDA approval reported; studied in clinical trials1,2 No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page does not list it.1,2 | In clinical trials In clinical trials; not FDA-approved3,4,5 Not FDA-approved. FDA lists survodutide among unapproved drugs it has warned companies for selling with false research-use labels.5 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.7 HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Efinopegdutide is not among them.7,8 | Not among the six peptides the policy lists.7 |
| FDA compounding safety-risk page | Not listed. FDA’s compounding safety-risk page, current as of April 22, 2026, does not list efinopegdutide.2 | Not addressed in this profile’s sources. |
| Kinds of studies cited | Smaller controlled human trials
|
|
| Records collected | 13 ClinicalTrials.gov records and 4 PubMed records collected | |
| Area of study | ||
| Latest dated events |
|
|
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1Efinopegdutide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 2Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 3BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver · record history version 50 · last update posted 2026-07-22 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 4ClinicalTrials.gov record NCT07754461 · retained source version 2026-08-10:d71d6065261ae9f1c83fbc9694b2dc6cef63964c1377569876a214c0a75eb88e ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 5FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 6Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial (2024) · PMID 38330987 ↗
The Lancet Diabetes & Endocrinology · Official source · Source checked November 14, 2026
- 7HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 8Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 9A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease (2023) · PMID 37355043 ↗
Journal of Hepatology · Official source · Source checked November 16, 2026
- 10Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1, 2026) · PMID 42253238 ↗
The New England Journal of Medicine · Official source · Source checked November 14, 2026
- 11A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (2024) · PMID 38847460 ↗
The New England Journal of Medicine · Official source · Source checked November 14, 2026
- 12Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial (2026) · PMID 42252333 ↗
Nature Medicine · Official source · Source checked November 14, 2026
- 13ClinicalTrials.gov record NCT06077864 · retained source version 2026-08-11:60e24ca2b3858aa7bfd06f0e1cac79051207229d8181cdbe15a0399bddf60984 ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026